Nanoemulsion has the potential to overcome several disadvantages in drug formulation. Nanoemulsions are nano-sized emulsions that can improve the bioavailability of drug molecules via various routes of administration. The development of nanoemulsion formulation is a challenging and lengthy process. Selecting components such as oil phase, surfactant, an optimum oil-to-surfactant ratio, and ideal process parameters are critical for developing a stable nanoemulsion. Development becomes more complicated when a drug molecule is sensitive to a variety of factors. This webinar discusses, with a case study, a nanoemulsion development process using a microfluidizer, and factors to consider while developing a sterile ophthalmic nanoemulsion formulation for a light, oxidation, and heat-sensitive molecule.

Frontage provides integrated solutions to our clients: Formulation, Product Development, Analytical Testing, from preclinical to clinical drug development, including commercial products.

Frontage’s CMC portfolio of services spans pre-formulation, drug product formulation development, analytical method development and validation, GLP batches, GMP clinical trial materials (manufacturing, labeling, packaging, and distribution), scale up, pilot and pivotal/registration batches, and commercial manufacturing (to be ready Q3 2024).

Our formulation development experience and capabilities cover a wide range of dosage forms for IND, NDA, ANDA and 505(b)(2) filings.